BioVie (BIVI) dosed the last patient in the Phase 2 ADDRESS-LC trial for Bezisterim in treating neurological symptoms of Long COVID. The “last patient dosed” milestone is a positive clinical development, though no efficacy/safety or readout timeline was provided, suggesting modest near-term impact for the stock.
BioVie (BIVI) dosed the last patient in the Phase 2 ADDRESS-LC trial for Bezisterim in treating neurological symptoms of Long COVID. The “last patient dosed” milestone is a positive clinical development, though no efficacy/safety or readout timeline was provided, suggesting modest near-term impact for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
